Memorial Sloan Kettering signs deal with Abintus Bio

By The Science Advisory Board staff writers

November 17, 2021 -- Memorial Sloan Kettering Cancer Center has agreed to allow its next generation signaling technology 1XX to be used in Abintus Bio's in vivo CAR X products.

The products have the potential to improve outcomes for patients with hematologic malignancies and solid tumors while overcoming the challenges of ex vivo CAR technologies, according to Abintus Bio. Currently, 1XX CARs are under clinical evaluation in multiple cancers.

In vivo CAR X products aim to simultaneously target both adaptive and innate immune effector cells, including active T cells and NK cells, to produce an immune response against hematologic malignancies and solid tumors.

Abintus' initial products targeting hematologic and solid tumors are poised to enter clinical evaluation in early 2023.

Innovation and safety remain key amid shifting pandemic-impacted clinical trial protocols
WASHINGTON, DC - During the pandemic, clinical trial execution for cancer therapies has been challenging, said Dr. Samit Hirawat, chief medical officer...
Leukemia & Lymphoma Society support next-gen cell therapies
The Leukemia & Lymphoma Society Therapy Acceleration Program announced five new investments aimed at speeding the development of new and improved...
Caribou inks deal with MSK to make allogeneic therapies
Memorial Sloan Kettering Cancer Center (MSK) has agreed to exclusively license its antibody fragments to CRISPR genome editing firm Caribou Biosciences...
Researchers explore the role of circular DNA in deadly childhood cancer
Researchers from Charité - University Medicine Berlin and the Memorial Sloan Kettering Cancer Center in New York combine genomic and transcriptomic...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter